Cargando…

Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239

Strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to elicit protective immunity against wild-type SIV(mac)239 infection of rhesus macaques by two different vaccine regimens. Six animals were inoculated at 8-week intervals wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Bin, Ng, Sharon K., DeGottardi, M. Quinn, Piatak, Michael, Yuste, Eloísa, Carville, Angela, Mansfield, Keith G., Li, Wenjun, Richardson, Barbra A., Lifson, Jeffrey D., Evans, David T.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621341/
https://www.ncbi.nlm.nih.gov/pubmed/19165322
http://dx.doi.org/10.1371/journal.ppat.1000272
_version_ 1782163395683811328
author Jia, Bin
Ng, Sharon K.
DeGottardi, M. Quinn
Piatak, Michael
Yuste, Eloísa
Carville, Angela
Mansfield, Keith G.
Li, Wenjun
Richardson, Barbra A.
Lifson, Jeffrey D.
Evans, David T.
author_facet Jia, Bin
Ng, Sharon K.
DeGottardi, M. Quinn
Piatak, Michael
Yuste, Eloísa
Carville, Angela
Mansfield, Keith G.
Li, Wenjun
Richardson, Barbra A.
Lifson, Jeffrey D.
Evans, David T.
author_sort Jia, Bin
collection PubMed
description Strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to elicit protective immunity against wild-type SIV(mac)239 infection of rhesus macaques by two different vaccine regimens. Six animals were inoculated at 8-week intervals with 6 identical doses consisting of a mixture of three different envelope variants of single-cycle SIV (scSIV). Six additional animals were primed with a mixture of cytoplasmic domain-truncated envelope variants of scSIV and boosted with two doses of vesicular stomatitis virus glycoprotein (VSV G) trans-complemented scSIV. While both regimens elicited detectable virus-specific T cell responses, SIV-specific T cell frequencies were more than 10-fold higher after boosting with VSV G trans-complemented scSIV (VSV G scSIV). Broad T cell recognition of multiple viral antigens and Gag-specific CD4(+) T cell responses were also observed after boosting with VSV G scSIV. With the exception of a single animal in the repeated immunization group, all of the animals became infected following an intravenous challenge with SIV(mac)239. However, significantly lower viral loads and higher memory CD4(+) T cell counts were observed in both immunized groups relative to an unvaccinated control group. Indeed, both scSIV immunization regimens resulted in containment of SIV(mac)239 replication after challenge that was as good as, if not better than, what has been achieved by other non-persisting vaccine vectors that have been evaluated in this challenge model. Nevertheless, the extent of protection afforded by scSIV was not as good as typically conferred by persistent infection with live, attenuated SIV. These observations have potentially important implications to the design of an effective AIDS vaccine, since they suggest that ongoing stimulation of virus-specific immune responses may be essential to achieving the degree of protection afforded by live, attenuated SIV.
format Text
id pubmed-2621341
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-26213412009-01-23 Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239 Jia, Bin Ng, Sharon K. DeGottardi, M. Quinn Piatak, Michael Yuste, Eloísa Carville, Angela Mansfield, Keith G. Li, Wenjun Richardson, Barbra A. Lifson, Jeffrey D. Evans, David T. PLoS Pathog Research Article Strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to elicit protective immunity against wild-type SIV(mac)239 infection of rhesus macaques by two different vaccine regimens. Six animals were inoculated at 8-week intervals with 6 identical doses consisting of a mixture of three different envelope variants of single-cycle SIV (scSIV). Six additional animals were primed with a mixture of cytoplasmic domain-truncated envelope variants of scSIV and boosted with two doses of vesicular stomatitis virus glycoprotein (VSV G) trans-complemented scSIV. While both regimens elicited detectable virus-specific T cell responses, SIV-specific T cell frequencies were more than 10-fold higher after boosting with VSV G trans-complemented scSIV (VSV G scSIV). Broad T cell recognition of multiple viral antigens and Gag-specific CD4(+) T cell responses were also observed after boosting with VSV G scSIV. With the exception of a single animal in the repeated immunization group, all of the animals became infected following an intravenous challenge with SIV(mac)239. However, significantly lower viral loads and higher memory CD4(+) T cell counts were observed in both immunized groups relative to an unvaccinated control group. Indeed, both scSIV immunization regimens resulted in containment of SIV(mac)239 replication after challenge that was as good as, if not better than, what has been achieved by other non-persisting vaccine vectors that have been evaluated in this challenge model. Nevertheless, the extent of protection afforded by scSIV was not as good as typically conferred by persistent infection with live, attenuated SIV. These observations have potentially important implications to the design of an effective AIDS vaccine, since they suggest that ongoing stimulation of virus-specific immune responses may be essential to achieving the degree of protection afforded by live, attenuated SIV. Public Library of Science 2009-01-23 /pmc/articles/PMC2621341/ /pubmed/19165322 http://dx.doi.org/10.1371/journal.ppat.1000272 Text en Jia et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Jia, Bin
Ng, Sharon K.
DeGottardi, M. Quinn
Piatak, Michael
Yuste, Eloísa
Carville, Angela
Mansfield, Keith G.
Li, Wenjun
Richardson, Barbra A.
Lifson, Jeffrey D.
Evans, David T.
Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239
title Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239
title_full Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239
title_fullStr Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239
title_full_unstemmed Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239
title_short Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239
title_sort immunization with single-cycle siv significantly reduces viral loads after an intravenous challenge with siv(mac)239
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621341/
https://www.ncbi.nlm.nih.gov/pubmed/19165322
http://dx.doi.org/10.1371/journal.ppat.1000272
work_keys_str_mv AT jiabin immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT ngsharonk immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT degottardimquinn immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT piatakmichael immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT yusteeloisa immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT carvilleangela immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT mansfieldkeithg immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT liwenjun immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT richardsonbarbraa immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT lifsonjeffreyd immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239
AT evansdavidt immunizationwithsinglecyclesivsignificantlyreducesviralloadsafteranintravenouschallengewithsivmac239